389results about "Mass spectrometric analysis" patented technology

A method of detecting one or more PFAS in a sample of animal tissue, comprising: spraying electrically charged solvent droplets onto the sample of animal tissue so as to generate analyte ions from analyte in the animal tissue; passing the analyte ions into a mass spectrometer; and mass analysing the analyte ions so as to determine if the one or more PFAS is in the animal tissue.

A novel 7-marker metabolite panel (7MetP) comprising or consisting of diacetylspermine, diacetylspermidine, N-(3-acetamidopropyl)pyrrolidin-2-one, N-acetylneuraminate, N-acetyl-mannosamine, N-acetyl-lactosamine, and hydroxyisobutyric acid is described.

The present invention relates to a mass spectrometric method for determining isomeric amino acid residues of a peptide and comprises the steps of: generating a list of peptide candidates using the amino acid lead sequence of the peptide, said lead sequence comprising positions of determined amino acid residues and at least one position with undetermined isomeric amino acid residues; predicting the collision cross section for each peptide candidate; comparing the predicted collision cross section of each peptide candidate with an experimentally determined collision cross section of the peptide and assigning the isomeric amino acid residues of the best matching peptide candidate to the isomeric amino acid residues of the peptide.

The present disclosure relates to a method and kits for detecting or determining the presence or likelihood of hyperglycemia in a subject. More particularly, the present invention relates to methods and kits for detecting or determining the likelihood of hyperglycemia in a subject based on a set of biomarkers in a breath sample, the biomarkers comprise at least one of cymene, butanol and pentanol.

A method of detecting vitamin D in blood using laser desorption / ionization mass spectrometry (LDI-MS) and an apparatus therefor according to the present invention are not complicated in a measurement, do not require a number of measurement steps, and allow for easy measurement and collection of results in real time with a quick analysis. In addition, precise analysis may be performed even at a lower concentration of a sample, such that sensitivity and precision are excellent, various subtypes of vitamin D may be simultaneously detected, a throughput is high, and structural analysis and quantitative analysis of vitamin D that has undergone a metabolic process in blood may be accurately performed without a matrix interference.

The present disclosure relates to biomarkers of metabolic syndrome. In particular, the present disclosure relates to the field of assessing the risk of metabolic syndrome and its complications. It introduces new biomarkers that can be used to predict metabolic syndrome and complications thereof.

Methods are provided for detecting the amount of one or more CAH panel analytes (i.e., pregnenolone, 17-OH pregnenolone, progesterone, 17-OH progesterone, dehydroepiandrosterone (DHEA), androstenedione, testosterone, deoxycorticosterone, 11-deoxycortisol, and cortisol) in a sample by mass spectrometry. The methods generally involve ionizing one or more CAH panel analytes in a sample and quantifying the generated ions to determine the amount of one or more CAH panel analytes in the sample. In methods where amounts of multiple CAH panel analytes are detected, the amounts of multiple analytes are detected in the same sample injection.

The object of the present invention is to provide a microsampling device that allows analysis of proteins in a biological sample, such as a whole blood sample, and provide methods of using the same.

Provided herein are methods and kits for identifying a pregnancy-associated risk or condition in a subject. In embodiments, the methods include detecting levels of at least one biomarker in a substantially cell-free cervical fluid sample obtained from the subject. In embodiments, the methods include detecting levels of biomarkers in a cervical fluid sample including extravillous trophoblasts (EVT) obtained from the subject.

A novel group of 7 marker metabolites (7MetP) is described, which comprises or consists of a diacetyl spermine, a diacetyl spermidine, an N-(3-acetamidopropyl) pyrrolidin-2-one, an N-acetylneuraminic acid ester, an N-acetyl-mannosamine, an N-acetyl-lactosamine, and a hydroxyisobutyric acid.

The invention relates to the quantitative measurement of steroidal compounds by mass spectrometry. In a particular aspect, the invention relates to methods for quantitative measurement of steroidal compounds from multiple samples by mass spectrometry.

Methods for differentiating full-length high molecular weight kininogen (HMWK) and cleaved HMWK in a sample are provided herein. Such methods may comprise treating a biological sample with a protease to generate a plurality of digested peptides, and measuring one or more signature peptides, which are indicative of cleaved HMWK and / or full-length HMWK.

To provide methods and related kits for detecting early stage pancreatic ductal adenocarcinoma, and methods of treating a patient susceptible, or suspected of being susceptible, to pancreatic ductal adenocarcinoma.SOLUTION: A method of determining susceptibility of a patient to pancreatic ductal adenocarcinoma is provided, the method comprising obtaining a biological sample from the patient, measuring the level of CA19-9 antigen in the biological sample, measuring the level of TIMP1 antigen in the biological sample, and measuring the level of LRG1 antigen in the biological sample, where the amounts of CA19-9 antigen, TIMP1 antigen, and LRG1 antigen classifies the patient as being susceptible to pancreatic ductal adenocarcinoma or not susceptible to pancreatic ductal adenocarcinoma.SELECTED DRAWING: None

The present invention provides a quality analysis device, an evaluation and calibration method thereof, an analysis method, and a reagent. The evaluation method of the quality analysis device includes: performing quality analysis on an ester of phthalic acid using the quality analysis device to detect a plurality of ions generated by dissociation of the ester of phthalic acid; and obtaining information on whether the quality analysis device is in a state suitable for analysis based on the intensity ratio of the plurality of detected ions.

The present disclosure relates to methods for diagnosing and evaluating a subject that has sustained or may have sustained an injury to the head, such as a traumatic brain injury (TBI). In particular, the present disclosure identifies various biomarkers, the detection and / or differential expression of which can be used to assess the presence or absence of a TBI in a subject, and can be used as a basis for diagnosing a subject as having a specific type of TBI (e.g., severe TBI or subclasses of mild TBI). The various TBI biomarkers can be detected individually or in combination and can be used as an important diagnostic, prognostic, and / or TBI risk stratification tool as part of assessing a subject's TBI status.

By adapting isotopic fingerprinting to the human body, experimental data revealed a specific chemical fingerprint of cancer, such as prostate cancer, "fossilized" in samples such as a patient's hair or nails. To interpret the isotopic chemical data of the samples, a predictive model was developed using machine learning algorithms and several dimensions to enable population differentiation. In several aspects, this provides a non-invasive method for cancer diagnosis, detection, or assessment developed by identifying the chemical fingerprint of cancer. TIFF2026509162000028.tif53159

Provided are methods for determining the amount of estrone in a sample using mass spectrometry. The methods generally involve ionizing estrone in a sample and detecting and quantifying the amount of the ion to determine the amount of estrone in the sample.

To provide methods of identifying and using glycopeptides as biomarkers for diagnosis and treatment monitoring.SOLUTION: Provided herein are methods of identifying new biomarkers for various diseases using proteomics, peptidomics, metabolics, proteoglycomics, glycomics, mass spectrometry and machine learning. The present disclosure also provides glycopeptides as biomarkers for various diseases such as cancer and autoimmune diseases.SELECTED DRAWING: Figure 1

The instant disclosure relates to methods which employ the detection of ADP-D-glycero-β-D-manno-heptose (ADP-heptose) in a biological sample obtained from an individual. In certain aspects, the methods comprise administering a treatment to an individual in which ADP-heptose is detected. The methods may further comprise determining whether the individual has clonal hematopoiesis of indeterminate potential (CHIP) and circulating ADP-heptose.

This invention provides compositions and treatment methods for reducing hyperphenylalaninemia. [Solution] A genetically modified bacterium is provided, comprising: a) one or more genes encoding phenylalanine ammonia lyase (PAL), which are operably linked to a promoter that is not naturally associated with the PAL gene and can be directly or indirectly induced; b) one or more genes encoding a phenylalanine transporter, which are not naturally associated with the phenylalanine transporter gene and can be operably linked to a promoter that is directly or indirectly induceable; and c) one or more genes encoding mutant fumarate and nitrate reductase (FNR), which are not naturally associated with the FNR gene and can be operably linked to a promoter that is directly or indirectly induceable.

An IROA Matrix of metabolite compounds is disclosed. Each of whose compounds has a molecular weight of 2000 AMU or less, and is present as first and second isotopomers that are equally present at two predetermined isotopomeric balances, and contain 2 to 10% of a first isotope, and 90 to 98% of a second isotope, respectively. A reagent pair for transforming a natural abundance mass spectral analysis metabolite sample into an IROA sample is also disclosed and comprises two reactively identical reagents that constitute first and second isotopomers containing 2 to 10% of a first isotope, and 90 to 98% of a second isotope, respectively. Each of the reagent pair contains the same reactive group that reacts with and bonds to a functional group of one or more compounds present in a composition of biologically-produced metabolite compounds. Methods of making and using the above and related materials are also disclosed.

The instant disclosure relates to methods which employ the detection of ADP-D-glycero-β-D- manno-heptose (ADP-heptose) in a biological sample obtained from an individual. In certain aspects, the methods comprise administering a treatment to an individual in which ADP- heptose is detected. The methods may further comprise determining whether the individual has clonal hematopoiesis of indeterminate potential (CHIP) and circulating ADP-heptose.

Provided are: a method which is for analyzing a neurogranin-related peptide and can suppress deviations in analysis results; and a method for preparing a biological sample containing the neurogranin-related peptide used for same. A method for preparing a sample solution containing a neurogranin-related peptide involves mixing a biological sample containing the neurogranin-related peptide with an organic solvent having a relative polarity of 0.200 to 0.700 to prepare a sample solution containing the organic solvent having a final concentration of at least 5.0 (v / v)%.

The invention belongs to the technical field of biological medicine, and particularly relates to application of a metabolic marker in preparation of a product for diagnosing abdominal aortic aneurysm. The metabolic marker comprises one or more than two of 5-delta-hydroxybutyl hydantoin, I-alpha-amino acid, PGF2 alpha, D-pyroglutamic acid, nicotine glucuronide, cysteine glutathione disulfide or Trp-P-1. Experiments prove that the metabolic marker has the advantages that the metabolic marker can be applied to the field of biomarkers, and the metabolic marker can be applied to the field of biomarkers; the seven metabolites are independently or jointly used as metabolic markers for diagnosing the abdominal aortic aneurysm and have good specificity and sensitivity.

The invention relates to a method for analyzing a biological sample for changes in signatures of key metabolites in a hepatic disease, comprising (a) isolating erythrocytes from the biological sample, (b) identifying and optionally quantifying lipids from the erythrocytes as the key metabolites for a hepatic and infectious disease, including the lipids PC (28:0), PC (30:0), PC (30:1), PC (32:0), PC (32:1), PC (34:0), PC (34:1), PC (34:2), PC (36:0), PC (36:1), PC (36:2), PC (36:3), PC (36:4), PC (38:0), PC (38:1), PC (38:2), PC (38:3) and PC (38:4); SM (17:0), SM (12:0), SM (14:0), SM (16:0), SM (18:0), SM (18:1), SM (20:0), SM (22:0), SM (24:0), SM (24:1), SM (26:0) and SM (26:1); LPE (16:0), LPE (16:1), LPE (18:0), LPE (18:1), LPE (18:2) and LPE (20:4); Cer (15:0), Cer (12:0), Cer (14:0), Cer (16:0), Cer (18:0), Cer (18:1), Cer (20:0), Cer (22:0), Cer (24:0) and Cer (24:1); LPC (16:0), LPC (16:1), LPC (17:0), LPC (18:0), LPC (18:1), LPC (18:2), LPC (20:0), LPC (20:1), LPC (20:3) and LPC (20:4), and LPE (16:0), LPE (16:1), LPE (17:1), LPE (18:0), LPE (18:1), LPE (18:2) and LPE (20:4); (c) carrying out principal component analysis of the samples and clustering according to subgroups; (d) identifying key metabolites by means of XGBoost algorithm; (e) detecting the changes in the key signatures of the key metabolites of the hepatic disease identified in step (d), and (f) diagnosing a hepatic disease. The invention further relates to the use of the results of this method in personalized medicine.

A quality control standard for peptide (including protein) measurement, and a quality control for peptide (including proteins) measurement are provided. A QC standard sample for measurement of a target peptide, the QC standard sample comprising: a blood sample comprising a peptide, and a peptide labeled with a stable isotope that is spiked into said blood sample. The target peptide to be measured includes, for example, at least one selected from the group consisting of Aβ1-42 (SEQ ID NO.: 9), Aβ1-38 (SEQ ID NO.: 11), Aβ1-40 (SEQ ID NO.: 7), and APP669-711 (SEQ ID NO.: 10). The peptide labeled with a stable isotope that is spiked into the blood sample includes, for example, at least one selected from the group consisting of SIL-Aβ1-42, SIL-Aβ1-38, SIL-Aβ1-40, and SIL-APP669-711.

The present disclosure provides methods and materials for screening a compound or monitoring a subject's response to a compound or dosing regimen for treating a PGRN-associated disorder. Methods and materials for identifying and treating a subject having a PGRN-associated disorder are also provided.

The present invention belongs to the technical field of cancer diagnosis, and specifically relates to biomarkers for lung cancer detection and their applications. The present invention has found, through research on non-small cell lung cancer, amino acid modifications with diagnostic and therapeutic significance in hemoglobin α subunit and β subunit and pulmonary surfactant-associated protein A1 of patients with non-small cell lung cancer, thereby providing a new non-small cell lung cancer detection marker. The difference in amino acids reveals from another level the impact of the diversity of biological macromolecules on the homeostasis of the body, and the abnormal modification or variation of macromolecules is the original inducing factor of many diseases, especially chronic diseases and cancer. Therefore, compared with conventional abnormal protein quantification, the present invention has earlier and more effective diagnostic value, as well as higher therapeutic reference value, and therefore has good practical application value.

Analysis of samples injected into an inductively coupled plasma source can be improved by one or more of a stabilizing solution that is mixable with the sample prior to injection and a heated injector. With relatively low amounts of dissolved solids (e.g., at or below about 0.2%), the stabilizing solution can minimize differences in osmotic pressure between the solution and the cells. The stabilizing solution can contain a salt (e.g., ammonium nitrate) present at a concentration of at least 5 mM. The injector can be heated before and / or during injection. In some cases, heat from adjacent portions can be directed into the injector to improve heating of the injector. An injector heated to a sufficient temperature can minimize solute accumulation and can extend the available time between cleanings. These improvements may be particularly useful in elemental analysis such as inductively coupled plasma mass spectrometry or inductively coupled plasma optical emission spectroscopy.